Navigation Links
Varian Medical Systems to Introduce RapidArc(TM) Radiotherapy Technology for Volumetric Arc Therapy at ASTRO 2007
Date:10/25/2007

pidArc plans can conform the treatment beam more closely to the tumor shape and protect more healthy tissues including the spinal cord, brain stem, eyes, optic nerve and chiasm, parotid glands, and brain," Wilson said.

RapidArc will also make it much simpler to plan and deliver IMRT by eliminating numerous steps required for conventional treatments that use multiple beam angles. By reducing the time it takes to deliver IMRT and other highly-precise forms of radiation therapy, RapidArc has the potential to improve the quality of care and of patient comfort, while making radiation oncology a more affordable treatment. "This can reduce the treatment waiting lists in parts of the world where capacity is a limiting factor," Wilson said.

"Clinicians everywhere are rapidly adopting image-guided radiotherapy," observed Karl Otto, PhD, medical physicist at the BC Cancer Agency, whose research has contributed to the development of Varian's RapidArc product. "With RapidArc, it is likely that we will see image-guided radiotherapy sessions complete much faster than they are now, including imaging and treatment."

"Varian's goal is to reduce the time it takes for imaging and treatment to under five minutes, through technology advancements," said Wilson. "With RapidArc, we're taking a big step in this direction."

RapidArc Technology

RapidArc technology utilizes a sophisticated algorithm that makes it possible to program a Varian linear accelerator to deliver a complete intensity-modulated radiation treatment in a single revolution. By varying three parameters simultaneously-the speed of rotation, the beam shaping aperture, and the dose delivery rate-doctors can create finely-shaped IMRT dose distributions that more closely match the size and shape of the tumor while sparing healthy tissues. "We have been working to develop and perfect RapidArc capability for more than five years and it is exciting to see this important technology coming to fruition," s
'/>"/>

SOURCE Varian Medical Systems
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Vitamin D Reduces Chances of Colon, Breast And Ovarian Cancers by 50%
3. Progestin protects against ovarian cancer
4. Inherited gene important in ovarian cancer
5. Blood test may identify ovarian cancer
6. Exercise lowers Risk of Ovarian Cancer
7. Screening device for ovarian cancer
8. Ethnic discrepancy in ovarian cancer
9. Gene variant foretells diabetic neuropathy
10. Associated scan for detecting ovarian cancer spread
11. Gene Mutation Causes Ovarian Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2008)... Open enrollment is now h...s cover expenses not covered by Medicare, and may ...any consumers are now shopping online for instant ... Fort Collins, CO (PRWEB) November 21, 2008 -- Me...ent for Medicare Supplement plans . Medicare Adv...
(Date:11/21/2008)...Finding may lead to new therapies for preterm labo...- Researchers say they,ve found the switch that ac... childbirth, a finding that may lead to therapies ... normally binds the protein IP on the surface of t... inactive during pregnancy. , But researchers ...
(Date:11/21/2008)..., TALLAHASSEE, Fla. -- A Florida State Universit...g Wang has discovered an important new layer of re...ead to a greater understanding of the way cancer b...cal sciences at the College of Medicine, said the ...ose cancer and could lead to the design of new dru...
(Date:11/21/2008)...LOVELAND, Colo., Nov. 21 ...ced it will present at the New York Society of,Se... Pharma Conference on,December 2, 2008 at 1177 Av...The presentation is scheduled to begin at 9:35 a.m... be available via live webcast and for two weeks,...
Breaking Medicine News(10 mins):Health News:MediGap Advisors Announces Open Enrollment for Medicare Supplement Plans 2
...pical cyclone Glenda has increased the spread of t...y Valley encephalitis// (MVE), in Western Australi... wet season in Kimberley has spread the virus that.... The cyclone Glenda along with the more recent cy...
...earcher, Professor Ian Frazer of the University of... Premier's Fellowship. The prestigious Fellowship ...r award for his work in developing a vaccine for c...ellowship, Professor Ian Frazer will get $250,000 ...
...eo game makers are now looking to extend their rea...tele is concerned. And a really ripe market awaits... to "Brain Train" concept like a duck to water.// ...s sold 3.3 million of its "Brain Training for Adul...
...ording to a senior Guangdong health official of Ch...this year's peak human bird flu season in the prov...de by other health specialists. The senior health...rector of the Guangdong Centre for Disease Control...
Other Medicine News:
(Date:11/19/2008)...e/ -- Biotech scientists increasingly are applying...etter understand the effects of novel drug candida...c Engineering & Biotechnology News ( GEN ). T...w compound,s mechanism of action and eventually de...ing to the November 15 issue of GEN . ( http://ww...
(Date:11/18/2008)...n more, make a donation or send a Christmas Seals ...USNewswire/ -- Millions will receive Christmas Sea...n Lung Association. These decorative holiday stamp...ng back to 1907 when the Lung Association led effo...ericans alive today have no vivid memories of how ...
(Date:11/18/2008)...gnosed, elderly AML patients , , PRINCETON,...cals today announced that the first patient has be...of CPX-351 (Cytarabine:Daunorubicin) Liposome Inje...id leukemia (AML). , , The first patient wa...al College of Cornell University and New York Pre...
(Date:11/12/2008)...wswire/ -- A new study being,published in this Fri...question, what causes Parkinson,s disease?, One o...rch into,Parkinson,s disease is what causes the se...ce. Answering this question has been especially di...es of brain cells that produce,dopamine and they a...
Breaking Medicine Technology:GEN Reports on the Trend Toward Predictive Toxicogenomics 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3A Window Into Parkinson's Disease 2LaVoie Group Adds Cancer Therapeutics Company Neotropix 28R 29 to Its Life Science Agency Roster 26846 1LaVoie Group Adds Cancer Therapeutics Company Neotropix 28R 29 to Its Life Science Agency Roster 26846 2Covance Decides to Pursue Its Original Preclinical Strategy in China 7954 1Covance Decides to Pursue Its Original Preclinical Strategy in China 7954 2Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month 26843 1Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month 26843 2Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month 26843 3Combined Insurance Encourages Women to Assess Insurance Plans and Protection During Breast Cancer Awareness Month 26843 4Austin Dentistry Clinic Now Offers Certified Full Service Sedation Dentistry All Gain No Pain 26841 1Austin Dentistry Clinic Now Offers Certified Full Service Sedation Dentistry All Gain No Pain 26841 2
...ot Study Demonstrates 50% Survival in Valortim-Tre..., March 29, 2007,/PRNewswire-FirstCall/ -- Medarex...d PharmAthene, Inc., a privately held,biotechnolog...se,countermeasures, today announced that Valortim(...didate being developed for the,prevention and trea...
...trations Reached in Key Lung Compartments, REINACH...e-FirstCall/ -- Arpida Ltd. today announced promis... These radiolabelled,Human Microdose studies inclu...groundbreaking study is the first ever using Micro...s in lung compartments.,The results showed that AR...
Other Medicine Technology:Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5
Low-profile, hand-held instrument.
Low-profile, hand-held instrument.
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries.
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries.
Medicine Products: